Quantcast

Latest Genmab Stories

2009-01-23 09:08:00

SCOTTSDALE, Ariz., Jan. 23 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published two new reports providing critical strategic insight for companies developing therapies to treat hematologic malignancies. These reports are based on primary interviews conducted with hematology experts from North America immediately following the American Society of Hematology (ASH) annual meeting. The first report, entitled...

2008-12-08 12:59:00

Data from a pivotal trial suggests that ofatumumab has activity in heavily pre-treated patients who have failed standard treatments PHILADELPHIA, Dec. 8 /PRNewswire-USNewswire/ -- GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today positive results from a pivotal trial pre-planned interim analysis of Arzerra(TM) (ofatumumab) in the treatment of refractory chronic lymphocytic leukemia (CLL). The results demonstrate the potential of ofatumumab for heavily pre-treated patients with...

2008-12-01 07:27:00

COPENHAGEN, December 1 /PRNewswire/ -- A strong pipeline makes the Copenhagen Region biotech cluster well prepared for the challenges ahead. With 185 drug candidates in preclinical and clinical development, Denmark ranks third in Europe. Only United Kingdom and Germany have a bigger pipeline. Also in term of pipeline growth Denmark has a strong position as it experienced the largest pipeline growth among the countries in Europe. These are the two main findings of the Ernst &...

2008-11-04 06:00:10

Having gained approval as a treatment for chronic lymphocytic leukemia earlier this year, the FDA has now extended Treanda's use to indolent B-cell non-Hodgkin's lymphoma. Although Treanda's total sales are set to increase following its approval in this more significant commercial market, Cephalon's drug is likely to face competition from pipeline drugs currently in late-stage development. Approval of Treanda for non-Hodgkin's lymphoma (NHL) followed the results of a Phase III trial in...

2008-10-30 18:00:29

Cytokinetics, Incorporated (NASDAQ: CYTK), reported revenues from research and development collaborations of $3.1 million for the third quarter of 2008. The net loss for the three months ended September 30, 2008, which included $2.5 million in restructuring charges, was $16.3 million, or $0.33 per share compared to a net loss of $11.3 million, or $0.24 per share for the same period in 2007. As of September 30, 2008, cash, cash equivalents, restricted cash and long-term investments totaled...

2008-10-10 12:00:42

COPENHAGEN, Denmark, October 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached the sixth milestone for ofatumumab (HuMax-CD20(R)) under the terms of its collaboration with GlaxoSmithKline (GSK). A milestone payment of approximately DKK 29 million (approximately USD 5.6 million) was triggered by the first patient receiving treatment in the ofatumumab Phase I study in relapsed/refractory follicular non-Hodgkin's lymphoma and chronic lymphocytic leukemia in...

2008-10-06 12:00:43

Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue. Therapeutic Monoclonal Antibodies Report 2008-2023 http://www.reportlinker.com/p096392/Therapeutic-Monoclonal-Antibodies-Report-2008-2023.html This brand new report investigates the global market for therapeutic monoclonal antibodies. While the pharmaceutical industry as a whole is suffering from single digit growth, thinner pipelines than before and...

2008-09-23 12:00:51

COPENHAGEN, September 23 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has completed recruitment of patients in the pivotal Phase III study of ofatumumab (HuMax-CD20(R)) in rituximab refractory follicular non-Hodgkin's lymphoma (NHL). Eighty-one patients receiving treatment at the 1000 mg dose level of ofatumumab have been recruited in the study. Data from these patients will be included in the primary efficacy analysis. An additional 31 patients were recruited at a 500...

2008-09-23 09:01:09

Genmab, an international biotechnology company, has completed recruitment of 56 previously untreated follicular non-Hodgkin's lymphoma patients in the Phase II study of ofatumumab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone. Patients in this open label study will be randomized into two dose groups of 28 patients each and will receive a total of six infusions of ofatumumab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)....

2008-09-22 09:00:58

COPENHAGEN, September 22 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has completed recruitment of 56 previously untreated follicular non-Hodgkin's lymphoma (NHL) patients in the Phase II study of ofatumumab (HuMax-CD20(R)) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). "We are happy to finish enrolment in this first study with ofatumumab in front line follicular NHL patients," said Lisa N. Drakeman, Ph.D., Chief Executive Officer...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related